Nuvectis Pharma Investor Presentation Deck slide image

Nuvectis Pharma Investor Presentation Deck

NXP800 Mechanism of Action NXP800 is a GCN2 kinase activator NXP800 activates GCN2 >> GCN2 activates the Integrated Stress Response (ISR) >> ISR activation causes a translational switch which includes downregulation of HSF1-regulated genes Non- acylated tRNA Stalled ribosome Recognition by GCN2 NXP800 GCN2 GCN2 GCN2 activation Created with BioRender.com NuvectisPharma, Inc. - elF2a phosphorylation elF2a Selective ATF4 translation ATF4 Dimerization Cap-dependent translation partner ATF4 Translational switch - including HSF1 regulated proteins Chronic activation: Autophagic and apoptotic cell death (CHOP and other validated PD markers) Stress-induced genes ATF4 was induced in vivo in SKOV3 xenografts; ATF4 Validated as biomarker for preclinical activity X5 G150 (GI50 = 8.5nM) Vehicle Clarke et al, ENA 2022 ATF4 Vinculin ATF4 induction observed in patient samples in the phase 1a 8
View entire presentation